Clinical trials: sponsored by Ono Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer NSCLC
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)
The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT07169708
- Where
- 9 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Primary Central Nervous System Lymphoma (PCNSL)
Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study
The goal of this observational study is to describe the real-world effectiveness and safety of tirabrutinib among relapsed or refractory PCNSL patients in Taiwan.
- Trial name
- REVEAL (NCT06714370)
- Where
- 6 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose…
- Trial name
- NCT04947319
- Testing
- Tirabrutinib
- Where
- 39 sites in United States
- Volunteers
- 119 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastric Cancer
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy…
- Trial name
- NCT06256328
- Testing
- ONO-4578, Oxaliplatin, Capecitabine
- Where
- 63 sites in Japan, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
This study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC)…
- Conditions
- Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer
- Trial name
- NCT06525246
- Testing
- ONO-7475, Osimertinib Mesylate
- Where
- 13 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Richter's Transformation
ONO-4538 Study in Patients With Richter's Transformation
Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation
- Trial name
- NCT06936943
- Testing
- ONO-4538
- Where
- 10 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Epilepsy, Generalized
ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
To investigate the efficacy and safety of ONO-2017 in combination with antiepileptics in Japanese epileptic patients with generalized tonic-clonic seizures.
- Trial name
- NCT06579573
- Testing
- Cenobamate
- Where
- 25 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Solid Tumor
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
This study is dose escalation study to evaluate the tolerability and safety of ONO-7914 alone and in combination with ONO-4538 in patients with advanced or metastatic solid tumors
- Trial name
- NCT06535009
- Testing
- ONO-7914, ONO-4538
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Epilepsies, Partial
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
- Trial name
- NCT06590896
- Testing
- Cenobamate
- Where
- 29 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
- Trial name
- NCT06538272
- Testing
- ONO-2910
- Where
- 30 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Non-small Cell Lung Cancer
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based…
- Trial name
- NCT02582125
- Testing
- ONO-4538
- Where
- 8 sites in Taiwan
- Volunteers
- 53 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic…
- Trial name
- NCT06538207
- Testing
- ONO-4578, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Non-small Cell Lung Cancer (NSCLC)
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based…
- Trial name
- NCT02175017
- Testing
- ONO-4538
- Where
- 10 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Plaque Psoriasis
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
This is an early phase study to assess the safety and tolerability of ONO-4685 in patients with psoriasis. In addition, the study will assess how the drug is distributed and eliminated by the body (pharmacokinetics) and how the…
- Trial name
- NCT05332704
- Testing
- ONO-4685
- Where
- 4 sites in Moldova, Romania and 1 more
- Volunteers
- 33 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acute Leukemia, Myelodysplastic Syndromes
A Study of ONO-7475 in Patients With Acute Leukemias
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability…
- Trial name
- NCT03176277
- Testing
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo…
- Trial name
- NCT03117049
- Testing
- ONO-4538, Carboplatin, Paclitaxel
- Where
- 135 sites in Japan, South Korea and 1 more
- Volunteers
- 550 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Recurrent Solid Tumors
ONO-4538 Phase I Study in Patients With Solid Tumor
The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate…
- Trial name
- NCT02261285
- Testing
- ONO-4538
- Where
- 5 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastric Cancer
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard…
- Trial name
- NCT02267343
- Testing
- ONO-4538
- Where
- 49 sites in Japan, South Korea and 1 more
- Volunteers
- 493 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Recurrent Solid Tumors
ONO-4538 Phase I Study in Patients With Solid Tumor
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to…
- Trial name
- NCT02261298
- Testing
- ONO-4538
- Where
- 5 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Healthy Volunteers
Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects
To investigate safety, tolerability and pharmacokinetics in Japanese and Caucasian subjects when ONO-2910 is administered as single and multiple doses orally.
- Trial name
- NCT04504760
- Testing
- ONO-2910
- Where
- Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.